Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call and Business Update
13 avr. 2021 16h03 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory...
Adamis Pharmaceuticals Provides an Update on ZIMHI™
12 avr. 2021 07h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the status of the company’s New Drug Application (NDA) relating to its...
Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the COVID-19 Challenged Hamster Model
15 mars 2021 09h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that in studies conducted at Galveston National Laboratory (GNL),...
Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19
22 févr. 2021 09h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that the U.S. Food and Drug Administration (“FDA”) has completed the...
Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate
17 févr. 2021 09h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications...
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock
02 févr. 2021 16h05 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), today announced the closing of its underwritten public offering of 46,621,621 shares of its common...
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
29 janv. 2021 09h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various...
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
28 janv. 2021 16h01 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various...
Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID-19 Patients
28 janv. 2021 09h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) in collaboration with the Human Immune Monitoring Center at Stanford University have...
Adamis Pharmaceuticals Provides Update On Its US Compounding Business
26 janv. 2021 09h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has entered into a non-binding letter of intent with a potential buyer for sale...